Enlivex (ENLV) Accumulated Expenses (2016 - 2025)
Enlivex (ENLV) posted quarterly Accumulated Expenses of $5.2 million for Q4 2025, up 83.17% year-over-year from $2.8 million in Q4 2024, and up 96.27% quarter-over-quarter from $2.7 million in Q3 2025.
Enlivex (ENLV) Accumulated Expenses (2016 - 2025) Analysis & Trends
Enlivex's Accumulated Expenses history runs 10 years deep, the most recent figure standing at $5.2 million for Q4 2025.
- In Q4 2025, Accumulated Expenses rose 83.17% year-over-year to $5.2 million; the TTM figure through Dec 2025 stood at $5.2 million (up 83.17% YoY), while the FY2025 annual figure was $5.2 million, up 83.17% from the prior year.
- Accumulated Expenses for Q4 2025 stood at $5.2 million, up from $2.7 million in the prior quarter.
- The five-year high for Accumulated Expenses was $5.2 million in Q4 2025, with the low at $2.5 million in Q2 2024.
- The 5-year median for Accumulated Expenses is $3.4 million (2021), against an average of $3.4 million.
- The sharpest annual moves came in 2021 and 2024: Accumulated Expenses jumped 421.03% in 2021, then dropped 28.87% in 2024.
- Enlivex's Accumulated Expenses stood at $3.8 million in 2021, then advanced by 21.33% to $4.7 million in 2022, then declined by 14.12% to $4.0 million in 2023, then decreased by 28.87% to $2.8 million in 2024, then jumped by 83.17% to $5.2 million in 2025.
- Business Quant data shows ENLV's Accumulated Expenses at $5.2 million in Q4 2025, $2.7 million in Q3 2025, and $2.8 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.21 Mn |
| Sep 30, 2025 | 2.66 Mn |
| Jun 30, 2025 | 2.79 Mn |
| Mar 31, 2025 | 2.61 Mn |
| Dec 31, 2024 | 2.85 Mn |
| Sep 30, 2024 | 2.70 Mn |
| Jun 30, 2024 | 2.54 Mn |
| Mar 31, 2024 | 2.97 Mn |
| Dec 31, 2023 | 4.00 Mn |
| Sep 30, 2023 | 3.55 Mn |
| Jun 30, 2023 | 3.44 Mn |
| Mar 31, 2023 | 3.97 Mn |
| Dec 31, 2022 | 4.66 Mn |
| Sep 30, 2022 | 3.36 Mn |
| Jun 30, 2022 | 3.43 Mn |
| Mar 31, 2022 | 4.27 Mn |
| Dec 31, 2021 | 3.84 Mn |
| Sep 30, 2021 | 2.88 Mn |
| Jun 30, 2021 | 3.23 Mn |
| Mar 31, 2021 | 3.42 Mn |